Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non‐small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum‐based chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Pierrillas, Philippe B., Hanley, Michael J., Zhang, Steven, Diderichsen, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197538/
https://www.ncbi.nlm.nih.gov/pubmed/35316867
http://dx.doi.org/10.1002/psp4.12785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197538/
https://www.ncbi.nlm.nih.gov/pubmed/35316867
http://dx.doi.org/10.1002/psp4.12785

Ejemplares similares